292 related articles for article (PubMed ID: 17298589)
1. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
2. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
[TBL] [Abstract][Full Text] [Related]
3. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
[TBL] [Abstract][Full Text] [Related]
4. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
5. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
6. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
Strojek K; Bebakar WM; Khutsoane DT; Pesic M; Smahelová A; Thomsen HF; Kalra S
Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654
[TBL] [Abstract][Full Text] [Related]
7. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
Dashora U; Ashwell SG; Home PD
Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
[TBL] [Abstract][Full Text] [Related]
8. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Horton ES; Foley JE; Shen SG; Baron MA
Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
11. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Hausmann M; Dellweg S; Osborn C; Heinemann L; Buchwald A; Rosskamp R; Genova P; Heise T
Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
[TBL] [Abstract][Full Text] [Related]
12. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
13. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
14. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
15. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
17. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
18. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes.
Vehkavaara S; Yki-Järvinen H
Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):325-30. PubMed ID: 14684428
[TBL] [Abstract][Full Text] [Related]
19. Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes.
Juurinen L; Tiikkainen M; Saltevo J; Nikkilä K; Lanki H; Leppävuori E; Kock T; Teikari-Myyrä T; Kauppinen-Mäkelin R; Kotronen A; Yki-Järvinen H
Diabet Med; 2009 Apr; 26(4):409-15. PubMed ID: 19388972
[TBL] [Abstract][Full Text] [Related]
20. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
